Literature DB >> 17220904

Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease.

H Church1, K Tylee, A Cooper, M Thornley, J Mercer, E Wraith, T Carr, A O'Meara, R F Wynn.   

Abstract

Hurler Syndrome is corrected by allogeneic BMT by the action of donor enzyme on recipient tissue. In this paper, we describe monitoring of 39 patients transplanted in two centres to determine donor chimerism, enzyme level and residual substrate - expressed as dermatan sulphate to chondroitin sulphate ratio. We show that in fully engrafted recipients, the enzyme level, expressed as mumol/g total protein/h, post-transplant is 24.2 from an unrelated donor and 10.2 from a heterozygote family donor (P<0.0001). There is a tight relationship between mean post-transplant enzyme level and residual substrate - Spearman's rank correlation coefficient (Rho) was -0.76 and -0.80 at 12 and 24 months, respectively (P<0.0001). We propose that these differences affect patient outcome. As unrelated donor transplant outcomes improve and especially given the higher levels of donor cell engraftment following cord transplants, our data might influence donor selection where only heterozygote-matched family members are available.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220904     DOI: 10.1038/sj.bmt.1705569

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy.

Authors:  Muhammad Ameer Saif; Brian W Bigger; Karen E Brookes; Jean Mercer; Karen L Tylee; Heather J Church; Denise K Bonney; Simon Jones; J Ed Wraith; Robert F Wynn
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

Review 2.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

Review 3.  Glycan-based biomarkers for mucopolysaccharidoses.

Authors:  Roger Lawrence; Jillian R Brown; Fred Lorey; Patricia I Dickson; Brett E Crawford; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2013-07-29       Impact factor: 4.797

4.  Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.

Authors:  Minke H de Ru; Linda van der Tol; Naomi van Vlies; Brian W Bigger; Carla E M Hollak; Lodewijk Ijlst; Wim Kulik; Henk van Lenthe; Muhammad A Saif; Tom Wagemans; Willem M van der Wal; Ronald J Wanders; Frits A Wijburg
Journal:  J Inherit Metab Dis       Date:  2012-09-19       Impact factor: 4.982

5.  Monitoring of Therapy for Mucopolysaccharidosis Type I Using Dysmorphometric Facial Phenotypic Signatures.

Authors:  Stefanie Kung; Mark Walters; Peter Claes; Peter LeSouef; Jack Goldblatt; Andrew Martin; Shanti Balasubramaniam; Gareth Baynam
Journal:  JIMD Rep       Date:  2015-03-03

6.  Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H).

Authors:  Chris J Gardner; Nicola Robinson; Tim Meadows; Robert Wynn; Andrew Will; Jean Mercer; Heather J Church; Karen Tylee; J Edmond Wraith; Peter E Clayton
Journal:  J Inherit Metab Dis       Date:  2011-01-21       Impact factor: 4.982

7.  Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I.

Authors:  Shunji Tomatsu; Adriana M Montaño; Toshihiro Oguma; Vu Chi Dung; Hirotaka Oikawa; Talita Giacomet de Carvalho; María L Gutiérrez; Seiji Yamaguchi; Yasuyuki Suzuki; Masaru Fukushi; Nobuo Sakura; Luis Barrera; Kazuhiro Kida; Mitsuru Kubota; Tadao Orii
Journal:  J Inherit Metab Dis       Date:  2010-02-17       Impact factor: 4.982

8.  Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome.

Authors:  Dao Pan; Anthony Sciascia; Charles V Vorhees; Michael T Williams
Journal:  Brain Res       Date:  2007-10-23       Impact factor: 3.252

Review 9.  Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism.

Authors:  Jessica M Sun; Joanne Kurtzberg
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

10.  Emerging stem cell therapies: treatment, safety, and biology.

Authors:  Joel Sng; Thomas Lufkin
Journal:  Stem Cells Int       Date:  2012-08-02       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.